ClinicalTrials.gg
RecruitingNCT07699471Updated Oct 29, 2026

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

A Phase 3 interventional study of Canvuparatide and Placebo in Hypoparathyroidism, sponsored by MBX Biosciences. Recruiting at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by MBX Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 29, 2026First site in Canada10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.

Planned enrollment
2nd of 34
160 · median 41
Started
2026
with 5 others
Phase 3
13 of 43
3 open now
Primary completion
2028-01
later than 5 of 11 live
Registered
42nd of 43
by date
Lead sponsor
3 of 43
MBX Biosciences

Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 2nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 42nd registered.

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

Browse Hypoparathyroidism studies →

Open to participants now

8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hypoparathyroidism with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).

03

Conditions studied

  • Hypoparathyroidism

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Is an adult ≥18 years of age.
  2. Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or HypoPT for at least 12 months prior to screening.
  3. Intact PTH level below the median value of the normal range
  4. Minimum requirement for a dose of calcitriol ≥0.5 μg/day, or alfacalcidol ≥1.0 μg/day and (elemental) calcium ≥1000 mg/day for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.
  5. Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg/dL (1.95 to 2.35 mmol/L).

Key Exclusion Criteria:

  1. Has a known history of pseudohypoparathyroidism
  2. abnormal hematology, clinical chemistry, or coagulation.
  3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism;
  4. Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization
  5. PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Canvuparatide

    Canvuparatide is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of canvuparatide via a manual SC injection. Dosing is once weekly.

    Drug: Canvuparatide

  • Placebo comparator
    Placebo

    Placebo is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of placebo via a manual SC injection. Dosing is once weekly.

    Other: Placebo

Interventions

  • • Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.

    Also known as: MBX 2109

  • OtherPlacebo

    • Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.

    Responder status is defined as a study participant who meets the following composite criteria: * Independence from active vitamin D * Independence from therapeutic doses of calcium (standing elemental calcium dose of ≤ 600 mg/day) * 2 consecutive albumin-adjusted serum calcium results in the normal range (8.3-10.6 mg/dL) (2.07-2.64 mmol/L) * No increase in study drug

    Time frame: 26 Weeks

07

Study locations

22 of 22 sites recruiting
  • MBX Biosciences Investigational Site
    Englewood, Colorado 80113, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Homestead, Florida 33030, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Lawrenceville, Georgia 30046, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Metairie, Louisiana 70002, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Jackson, Mississippi 39202, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Omaha, Nebraska 68198, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Las Vegas, Nevada 89148, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Reno, Nevada 89511, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Albany, New York 12208, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Syracuse, New York 13210, United States
    Recruiting
  • MBX Biosciences Investigational Site
    The Bronx, New York 10467, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Greenville, North Carolina 27834, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Columbus, Ohio 43210, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Summerville, South Carolina 29485, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Dallas, Texas 75208, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Edinburg, Texas 78539, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Round Rock, Texas 78681, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Shavano Park, Texas 78231, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Weslaco, Texas 78596, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Spokane, Washington 99216, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Madison, Wisconsin 53706, United States
    Recruiting
  • MBX Biosciences Investigational Site
    Oakville, Ontario, Canada
    Recruiting
08

References and documents

Related links

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.

Of 15 phase 3 interventional studies under Hypoparathyroidism, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 86. This study's planned 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Aug 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first site in Canada
Show 10 added (9 United States, 1 Canada)
  • MBX Biosciences Investigational Site · Englewood, United States
  • MBX Biosciences Investigational Site · Lawrenceville, United States
  • MBX Biosciences Investigational Site · Jackson, United States
  • MBX Biosciences Investigational Site · Syracuse, United States
  • MBX Biosciences Investigational Site · The Bronx, United States
  • MBX Biosciences Investigational Site · Columbus, United States
  • MBX Biosciences Investigational Site · Edinburg, United States
  • MBX Biosciences Investigational Site · Oakville, Canada
  • MBX Biosciences Investigational Site · Omaha, United States
  • MBX Biosciences Investigational Site · Madison, United States
across 4 updates, Oct 13, 2026 – Oct 29, 2026
Show all 4 updates
  1. Oct 29, 2026
    1 site added
    Show site
    • MBX Biosciences Investigational Site · Madison, United States
  2. Oct 23, 2026
    1 site added
    Show site
    • MBX Biosciences Investigational Site · Omaha, United States
  3. Oct 20, 2026
    1 site added — first site in Canada
    Show site
    • MBX Biosciences Investigational Site · Oakville, Canada
  4. Oct 13, 2026
    7 sites added
    Show 7 added (7 United States)
    • MBX Biosciences Investigational Site · Englewood, United States
    • MBX Biosciences Investigational Site · Lawrenceville, United States
    • MBX Biosciences Investigational Site · Jackson, United States
    • MBX Biosciences Investigational Site · Syracuse, United States
    • MBX Biosciences Investigational Site · The Bronx, United States
    • MBX Biosciences Investigational Site · Columbus, United States
    • MBX Biosciences Investigational Site · Edinburg, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07699471
Lead sponsor
MBX Biosciences
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Aug 26, 2026
Primary completion
Jan 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Salomon Azoulay, MD
Contact
13176590200

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Canvuparatide

Start the discussion